| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | R2; RR2M |
| Entrez GeneID | 6241 |
| WB Predicted band size | Calculated MW: 45 kDa; Observed MW: 45 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human RRM2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是几条关于RRM2抗体的模拟参考文献(基于典型研究内容，非真实文献)。如需真实文献，请通过PubMed或Google Scholar查询：
1. **文献名称**：*"Development and Validation of a Novel Anti-RRM2 Antibody for Immunohistochemical Analysis in Solid Tumors"*
**作者**：Chen L, et al.
**摘要**：本研究开发了一种高特异性的人源RRM2单克隆抗体，并通过免疫组化验证其在乳腺癌、肺癌等肿瘤组织中的检测效果，证实RRM2表达与肿瘤增殖和化疗耐药性相关。
2. **文献名称**：*"RRM2 as a Prognostic Biomarker: Antibody-Based Detection in Colorectal Cancer Clinical Samples"*
**作者**：Wang Y, et al.
**摘要**：通过商业化RRM2抗体对结直肠癌患者组织样本进行染色分析，发现RRM2高表达与患者总生存期缩短显著相关，提示其作为预后标志物的潜在价值。
3. **文献名称**：*"Targeting RRM2 with a Neutralizing Antibody Inhibits DNA Synthesis and Enhances Chemosensitivity in Pancreatic Cancer"*
**作者**：Smith JR, et al.
**摘要**：报道了一种靶向RRM2的中和抗体，可阻断其酶活性并抑制胰腺癌细胞DNA合成，联合吉西他滨治疗显著增强化疗敏感性。
4. **文献名称**：*"Comparative Study of Commercial RRM2 Antibodies for Western Blot and Flow Cytometry Applications"*
**作者**：Gomez M, et al.
**摘要**：系统评估了多种市售RRM2抗体的特异性、灵敏度和适用性，为不同实验场景(如蛋白印迹、流式细胞术)提供抗体选择指南。
---
**注意**：以上为模拟摘要，真实文献需通过学术数据库(如PubMed、Web of Science)检索关键词“RRM2 antibody”或“RRM2 immunohistochemistry”获取。
The ribonucleotide reductase subunit M2 (RRM2) is a critical enzyme involved in DNA synthesis and repair, catalyzing the conversion of ribonucleotides to deoxyribonucleotides—a rate-limiting step in DNA replication. Overexpression of RRM2 is closely associated with tumorigenesis, cancer progression, and therapeutic resistance, making it a potential biomarker and therapeutic target in various cancers, including colorectal, breast, and pancreatic malignancies.
RRM2 antibodies are essential tools for studying its biological functions and clinical relevance. These antibodies are designed to specifically recognize and bind to RRM2. enabling researchers to quantify its expression levels in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), or immunofluorescence. Commercially available RRM2 antibodies are typically validated for specificity and sensitivity, often targeting conserved regions of the protein.
In research, RRM2 antibodies have been pivotal in elucidating the protein's role in cell cycle regulation, DNA damage response, and its interaction with oncogenic signaling pathways (e.g., PI3K/AKT). Clinically, they aid in correlating RRM2 expression with patient prognosis or chemotherapeutic outcomes. Recent studies also explore RRM2's involvement in antiviral responses and immune evasion, expanding its relevance beyond oncology. However, challenges remain in standardizing antibody performance across experimental conditions and ensuring reproducibility in clinical applications.
×
